Literature DB >> 16995328

Bioavailability and pharmacokinetics of Echinacea purpurea preparations and their interaction with the immune system.

K Woelkart1, E Marth, A Suter, R Schoop, R B Raggam, C Koidl, B Kleinhappl, R Bauer.   

Abstract

Echinacea is a widely used herbal remedy for the prevention and treatment of the common cold. Recently, many new insights concerning the molecular mode of action of the main lipophilic constituents, the alkamides, have renewed interest in this plant. In order to compare the bioavailability of alkamides from liquid and tablet preparations of E. purpurea (Echinaforce) in humans and to study the effects on ex vivo stimulated blood cells, a randomized, single-dose, crossover study with 10 (8 test, 2 placebo) volunteers has been performed. They received either 4 ml of the standardized E. purpurea (Echinaforce) tincture or 12 E. purpurea (Echinaforce) tablets or placebo. Both doses contained the same amount (0.07 mg) of the major alkamides, dodeca-2E,4E,8Z, 10E/Z-tetraenoic acid isobutylamides. Liquid chromatography electrospray ionization ion-trap mass spectrometry was used to determine the content of alkamides in serum. It was found that the arithmetic mean C(max) of dodeca-2E,4E, 8Z,10E/Z-tetraenoic acid isobutylamides absorbed after oral application of the Echinaforce tincture appeared after 30 min (0.40 ng/ml serum). In comparison, the t(max) of tablets was 45 min with a C(max) of 0.12 ng/ml. An ex vivo stimulation of blood by LPS was carried out to measure the influence of E. purpurea on the innate and adaptive immune system. Both E. purpurea preparations led to the same effects on the immune system according to the concentration of pro-inflammatory cytokines TNF-alpha and IL-8. 23 hours after oral application a significant down-regulation of TNF-alpha and IL-8 in LPS pre-stimulated whole blood was found. However, no significant changes in the concentration of IL-6 were observed. Although a quarter of the dodeca-2E,4E,8Z, 10E/Z-tetraenoic acid isobutylamides was absorbed from the tablets, the study shows that the formulations trigger the same effects on the measured immune parameters.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16995328     DOI: 10.5414/cpp44401

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  12 in total

1.  Pharmacokinetic and pharmacodynamic interactions of echinacea and policosanol with warfarin in healthy subjects.

Authors:  Mohi Iqbal Mohammed Abdul; Xuemin Jiang; Kenneth M Williams; Richard O Day; Basil D Roufogalis; Winston S Liauw; Hongmei Xu; Anita Matthias; Reginald P Lehmann; Andrew J McLachlan
Journal:  Br J Clin Pharmacol       Date:  2010-05       Impact factor: 4.335

2.  Echinacea for treating the common cold: a randomized trial.

Authors:  Bruce Barrett; Roger Brown; Dave Rakel; Marlon Mundt; Kerry Bone; Shari Barlow; Tola Ewers
Journal:  Ann Intern Med       Date:  2010-12-21       Impact factor: 25.391

Review 3.  Echinacea for preventing and treating the common cold.

Authors:  Marlies Karsch-Völk; Bruce Barrett; David Kiefer; Rudolf Bauer; Karin Ardjomand-Woelkart; Klaus Linde
Journal:  Cochrane Database Syst Rev       Date:  2014-02-20

4.  Alcohol extracts of Echinacea inhibit production of nitric oxide and tumor necrosis factor-alpha by macrophages in vitro.

Authors:  Zili Zhai; Devon Haney; Lankun Wu; Avery Solco; Patricia A Murphy; Eve S Wurtele; Marian L Kohut; Joan E Cunnick
Journal:  Food Agric Immunol       Date:  2007-09       Impact factor: 3.101

5.  Echinacea tennesseensis ethanol tinctures harbor cytokine- and proliferation-enhancing capacities.

Authors:  David S Senchina; Dustin A McCann; Gina N Flinn; Lankun Wu; Zili Zhai; Joan E Cunnick; Eve S Wurtele; Marian L Kohut
Journal:  Cytokine       Date:  2009-03-14       Impact factor: 3.861

6.  The effect of Echinacea purpurea on the pharmacokinetics of docetaxel.

Authors:  Andrew K L Goey; Irma Meijerman; Hilde Rosing; Jacobus A Burgers; Marja Mergui-Roelvink; Marianne Keessen; Serena Marchetti; Jos H Beijnen; Jan H M Schellens
Journal:  Br J Clin Pharmacol       Date:  2013-09       Impact factor: 4.335

7.  Comparison of alkylamide yield in ethanolic extracts prepared from fresh versus dry Echinacea purpurea utilizing HPLC-ESI-MS.

Authors:  Kevin Spelman; Matthew H Wetschler; Nadja B Cech
Journal:  J Pharm Biomed Anal       Date:  2009-02-20       Impact factor: 3.935

8.  Echinacea purpurea (L.) Moench treatment of monocytes promotes tonic interferon signaling, increased innate immunity gene expression and DNA repeat hypermethylated silencing of endogenous retroviral sequences.

Authors:  Ken Declerck; Claudina Perez Novo; Lisa Grielens; Guy Van Camp; Andreas Suter; Wim Vanden Berghe
Journal:  BMC Complement Med Ther       Date:  2021-05-12

9.  Effect of echinalkamide identified from Echinacea purpurea (L.) Moench on the inhibition of osteoclastogenesis and bone resorption.

Authors:  Bo Yoon Chang; Seul Ki Lee; Da Eun Kim; Jin Hye Bae; Thanh Tam Ho; So-Young Park; Mi Kyeong Lee; Sung Yeon Kim
Journal:  Sci Rep       Date:  2020-07-02       Impact factor: 4.379

10.  Safety of Herbal Medicinal Products: Echinacea and Selected Alkylamides Do Not Induce CYP3A4 mRNA Expression.

Authors:  Maryam Modarai; Elisabete Silva; Andy Suter; Michael Heinrich; Andreas Kortenkamp
Journal:  Evid Based Complement Alternat Med       Date:  2010-09-15       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.